香港潮商集团(02322.HK)订立补充循环保理融资协议 融资最高金额增至2500万元
格隆汇8月28日丨香港潮商集团(02322.HK)公布,于2019年1月11日,公司间接全资附属公司仁瑞保理与该客户订立循环保理融资协议,据此,仁瑞保理同意于循环保理融资协议日期起计直至2020年12月31日止期间,向该客户提供保理本金额最高达人民币1000万元的循环保理融资,以换取保理利息及向仁瑞保理转让该客户之应收账款。
于2019年8月28日,仁瑞保理与该客户订立补充循环保理融资协议,据此,仁瑞保理及该客户已各自同意(i)将循环保理融资的最高金额由人民币1000万元修订为人民币2500万元;及(ii)修订融资期,以延长至2021年8月19日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.